2. Academic Validation
  3. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases

Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases

  • Eur J Med Chem. 2022 Apr 5:233:114227. doi: 10.1016/j.ejmech.2022.114227.
Dexiang Hua 1,  Xiaoxing Wu 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
  • 2 State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: wu_xiaoxing@cpu.edu.cn.
PMID: 35247754 DOI: 10.1016/j.ejmech.2022.114227
Abstract

SUMOylation is a key post-translational modification that involves the covalent attachment of small ubiquitin-like modifier (SUMO) to the lysine residues of target proteins. The well-balanced SUMOylation is essential for normal cellular behaviors, while disturbance of SUMOylation is associated with various cancers and Other Diseases. Herein, we summarize the structures and biological functions of proteins involved in the SUMOylation process, their dysregulation in human diseases, and the discovery of small-molecular inhibitors targeting this pathway. In addition, we highlight the emerging trends in this field.

Keywords

Cancer; Inhibitor; Post-translational modification; SENP; SUMO.

Figures